GELS Gelteq Limited: חוב להון עצמי

Gelteq Limited (GELS) generates revenue by licensing molecule encapsulation methods into gels, collecting royalties from tech giants without incurring capital expenditures. Current price action for the total debt-to-equity ratio stands at 0.34, which complements the profile of this unique drug delivery manufacturer. The company is currently focusing on organic tests, seeking a global partner for patent transfers without a merger.

This metric determines the degree of financial leverage, calculated as the ratio of total liabilities to net shareholders' equity to assess the business's dependence on borrowed funds. The trend of the total debt-to-equity ratio allows for monitoring the stability of Gelteq Limited during the scaling of commercial sales, given the high cost of R&D in the field of gel drug delivery systems.